Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neurology International|December 23, 2021
Multiple Sclerosis, Viruses, and New VaccinesPeter A C Maple
Vaccines|June 2, 2021
Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English PerspectivePeter A C Maple
Vaccines|December 23, 2015
Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control ProgramsPeter A C Maple
Vaccines|January 24, 2020
Cytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine DevelopmentPeter A C Maple
Vaccines|February 28, 2023
COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses InfectionsPeter A C Maple
Vaccines|June 27, 2025
Human Alpha Herpesviruses Infections (HSV1, HSV2, and VZV), Alzheimer's Disease, and the Potential Benefits of Targeted Treatment or Vaccination-A Virological PerspectivePeter A C Maple, Akram A Hosseini
The Journal of Infection|November 4, 2019
A different response to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controlsPeter A C Maple, Radu Tanasescu, Bruno Gran, et al.
Transfusion|June 1, 2013
Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samplesPeter A C Maple, Stuart Beard, Ruth P Parry, et al.
Vaccines|September 3, 2020
An Absence of Epstein-Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm VaccinationPeter A C Maple, Bruno Gran, Radu Tanasescu, et al.
Pediatric Blood & Cancer|May 3, 2014
Varicella zoster immune status in children treated for acute leukemiaSoonie R Patel, Jessica Bate, Peter A C Maple, et al.
Pageof 2